EXHIBIT 99.2
MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
THIRD QUARTER
2004
NET PRODUCT SALES DETAIL (MILLIONS OF DOLLARS)
<Table>
<Caption>
3Q `04 vs. 3Q `03
--------------------------------------------------------------------------
TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN
PRODUCT % CHG $ % CHG $ % CHG $
------- ------ ------- ------- ------- -------
AGGRASTAT -25% 19 N/A -- 4% 19
ARCOXIA * 61 N/A -- * 61
CANCIDAS 40% 109 35% 65 49% 43
COZAAR / HYZAAR 14% 706 13% 260 14% 446
CRIXIVAN / STOCRIN 1% 65 -43% 9 14% 56
EMEND * 14 * 13 * 1
FOSAMAX 13% 778 7% 443 22% 335
INVANZ 43% 16 27% 11 94% 5
MAXALT -17% 84 -24% 57 2% 27
PRIMAXIN -5% 162 -27% 42 6% 119
PROPECIA 14% 67 22% 33 8% 34
PROSCAR 42% 180 94% 91 12% 89
SINGULAIR 2% 626 -6% 447 26% 179
TIMOPTIC / TIMOPTIC XE -1% 38 -53% 2 6% 36
TRUSOPT / COSOPT 15% 138 19% 60 12% 78
VASOTEC / VASERETIC -8% 170 N/A -- -10% 170
VIOXX (1) -66% 175 -43% 148 -89% 27
ZOCOR -13% 1,221 -14% 854 -10% 366
HEPATITIS VACCINES -32% 48 -35% 40 -14% 8
VIRAL VACCINES 5% 167 3% 154 28% 13
OTHER VACCINES 2% 82 -1% 65 17% 17
</Table>
- ----------
* 100% or over
N/A - Not Applicable
(1) Includes adjustments of $-492 related to the withdrawal of Vioxx for
customer returns of product previously sold.
TOTAL SALES: VOLUME, PRICE, EXCHANGE
<Table>
<Caption>
3Q '04 % CHG. VOL PX FX
------- ------ ------- ------- -------
TOTAL PHARMACEUTICAL SALES $ 5,538 -4% -7 1 2
------- ------ ------- ------- -------
U.S. ($ MM) 3,390 -4% -8 4 N/A
Foreign ($ MM) 2,148 -4% -7 -3 6
</Table>
EXHIBIT 99.2
MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
YEAR-TO-DATE
2004
NET PRODUCT SALES DETAIL (MILLIONS OF DOLLARS)
<Table>
<Caption>
SEPTEMBER YTD `04 vs. SEPTEMBER YTD `03
TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN
PRODUCT % CHG $ % CHG $ % CHG $
------- ------ ------- ------- ------- -------
AGGRASTAT -15% 63 N/A -- 9% 63
ARCOXIA * 153 N/A -- * 153
CANCIDAS 61% 298 56% 172 67% 125
COZAAR / HYZAAR 15% 2,060 10% 735 18% 1,325
CRIXIVAN / STOCRIN -15% 193 -73% 21 14% 173
EMEND 55% 29 46% 27 * 2
FOSAMAX 15% 2,329 5% 1,323 31% 1,006
INVANZ 71% 44 53% 31 * 13
MAXALT -5% 218 -14% 137 16% 82
PRIMAXIN -3% 465 -29% 108 9% 357
PROPECIA 11% 195 12% 94 11% 101
PROSCAR 23% 539 35% 269 13% 270
SINGULAIR 26% 1,891 23% 1,327 33% 564
TIMOPTIC / TIMOPTIC XE -2% 114 -41% 7 2% 107
TRUSOPT / COSOPT 16% 402 16% 169 16% 233
VASOTEC / VASERETIC -3% 537 N/A -- -5% 537
VIOXX (1) -18% 1,489 -20% 891 -15% 599
ZOCOR 2% 3,886 13% 2,713 -17% 1,173
HEPATITIS VACCINES -20% 151 -22% 124 -6% 27
VIRAL VACCINES 2% 419 -- 383 28% 36
OTHER VACCINES -5% 180 -8% 139 8% 41
</Table>
- ----------
* 100% or over
N/A - Not Applicable
(1) Includes adjustments of $-492 related to the withdrawal of Vioxx for
customer returns of product previously sold.
TOTAL SALES: VOLUME, PRICE, EXCHANGE
<Table>
<Caption>
YTD `04 % CHG. VOL PX FX
------- ------ ------- ------- -------
TOTAL PHARMACEUTICAL SALES $17,191 2% -2 1 3
------- ------ ------- ------- -------
U.S. ($ MM) 10,099 -1% -4 3 N/A
Foreign ($ MM) 7,091 6% 0 -3 8
</Table>
EXHIBIT 99.2
MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
THIRD QUARTER
2004
================================================================================
OTHER (INCOME)/EXPENSE, NET FROM CONTINUING OPERATIONS (MILLIONS OF DOLLARS)
<Table>
<Caption>
3Q `04 3Q `03 YTD 2004 YTD 2003
---------- ---------- ---------- ----------
INTEREST INCOME $ (75.7) $ (66.9) $ (209.8) $ (236.5)
INTEREST EXPENSE 72.4 81.1 216.8 270.9
EXCHANGE (GAINS)/LOSSES 2.8 (1.7) 9.9 (25.1)
MINORITY INTERESTS 37.6 39.1 114.0 131.5
AMORTIZATION OF INTANGIBLES 4.6 4.4 14.3 14.9
Other, net (45.9) (38.9) (385.2) (270.2)
---------- ---------- ---------- ----------
TOTAL $ (4.2) $ 17.1 $ (240.0) $ (114.5)
---------- ---------- ---------- ----------
</Table>
JOINT VENTURE SALES DETAIL (MILLIONS OF DOLLARS)
All sales reported here are end-market JV sales, presented on a "NET" basis.
<Table>
<Caption>
MERIAL 3Q `04 3Q `03 YTD 2004 YTD 2003
---------- ---------- ---------- ----------
IVOMEC, HEARTGARD, other avermectins $ 139 $ 141 $ 335 $ 352
FRONTLINE 224 183 569 485
Biologicals 120 106 343 306
Other Animal Health 55 55 165 152
Poultry Breeding 36 38 107 113
---------- ---------- ---------- ----------
TOTAL MERIAL SALES $ 574 $ 523 $ 1,519 $ 1,408
---------- ---------- ---------- ----------
</Table>
<Table>
<Caption>
AVENTIS PASTEUR-MSD 3Q `04 3Q `03 YTD 2004 YTD 2003
---------- ---------- ---------- ----------
HEPATITIS VACCINES $ 20 $ 18 $ 61 $ 55
VIRAL VACCINES 15 16 42 40
Other Vaccines 239 200 483 404
---------- ---------- ---------- ----------
TOTAL AP-MSD SALES $ 274 $ 234 $ 586 $ 499
---------- ---------- ---------- ----------
</Table>
<Table>
<Caption>
MERCK / SCHERING-PLOUGH COLLABORATION 3Q `04 3Q `03 YTD 2004 YTD 2003
---------- ---------- ---------- ----------
VYTORIN (Worldwide) $ 52 $ -- $ 56 $ --
ZETIA (Worldwide) 293 136 725 305
---------- ---------- ---------- ----------
TOTAL $ 345 $ 136 $ 781 $ 305
---------- ---------- ---------- ----------
</Table>